Flavopiridol hydrochloride

CAS No. 131740-09-5

Flavopiridol hydrochloride( HL 275 | NSC 649890 | MDL 107826A | | Alvocidib Hydrochloride )

Catalog No. M11289 CAS No. 131740-09-5

A potent, ATP-competetive CDKs inhibitor with IC50 of 30, 170, 100 nM for CDk1, 2, 4, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Flavopiridol hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, ATP-competetive CDKs inhibitor with IC50 of 30, 170, 100 nM for CDk1, 2, 4, respectively.
  • Description
    A potent, ATP-competetive CDKs inhibitor with IC50 of 30, 170, 100 nM for CDk1, 2, 4, respectively; inhibits cell cycle progression in either G1 or G2 in human breast carcinoma cells, induces programmed cell death, promote differentiation, inhibits angiogenic processes and modulates transcriptional events.Blood Cancer Phase 2 Clinical(In Vitro):Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopiridol.
  • In Vitro
    Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopiridol.
  • In Vivo
    ——
  • Synonyms
    HL 275 | NSC 649890 | MDL 107826A | | Alvocidib Hydrochloride
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK1|CDK2|CDK4|CDK6|CDK7
  • Research Area
    Cancer
  • Indication
    Blood cancer

Chemical Information

  • CAS Number
    131740-09-5
  • Formula Weight
    438.3011
  • Molecular Formula
    C21H21Cl2NO5
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl
  • Chemical Name
    4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-, hydrochloride (1:1)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. De Azevedo WF Jr, et al. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2735-40. 2. Carlson BA, et al. Cancer Res. 1996 Jul 1;56(13):2973-8. 3. Senderowicz AM, et al. Invest New Drugs. 1999;17(3):313-20. 4. Kim KS, et al. J Med Chem. 2000 Nov 2;43(22):4126-34.
molnova catalog
related products
  • AT-7519

    A potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).

  • CLK1/2-IN-3

    CLK1/2-IN-3 (Cpd-3) is a potent and selective CLK1 and CLK2 inhibitor with antiproliferative activity and inhibits the activities of CLK1, CLK2, SRPK1, SRPK2, and SRPK3.CLK1/2-IN-3 induces nuclear speckle enlargement.

  • 9-Isopropylolomoucin...

    9-Isopropylolomoucine (N9-Isopropylolomoucine), a cell cycle protein-dependent kinase inhibitor, is a thiopurine.